ADRA2C — Alpha-2C Adrenergic Receptor

ADRA2C — Alpha-2C Adrenergic Receptor

Introduction

The ADRA2C gene encodes the alpha-2C adrenergic receptor (α2C-AR), a G protein-coupled receptor that mediates sympathetic tone inhibition. The α2C subtype is widely expressed in the central nervous system and peripheral tissues, playing crucial roles in regulating norepinephrine signaling, autonomic function, and stress responses. The receptor is unique among α2-AR subtypes for its distinctive subcellular distribution and functional properties[@szot2006].

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">ADRA2C Gene</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>ADRA2C</td></tr>
<tr><td><strong>Full Name</strong></td><td>Adrenoceptor Alpha 2C</td></tr>
<tr><td><strong>Chromosomal Location</strong></td><td>4p16.3</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[152](https://www.ncbi.nlm.nih.gov/gene/152)</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000141449</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[P21917](https://www.uniprot.org/uniprot/P21917)</td></tr>
<tr><td><strong>Protein Size</strong></td><td>462 amino acids</td></tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
</div>

Protein Structure

Transmembrane Domain Architecture

ADRA2C encodes a 462-amino acid GPCR with canonical seven transmembrane domain structure:

ADRA2C — Alpha-2C Adrenergic Receptor

Introduction

The ADRA2C gene encodes the alpha-2C adrenergic receptor (α2C-AR), a G protein-coupled receptor that mediates sympathetic tone inhibition. The α2C subtype is widely expressed in the central nervous system and peripheral tissues, playing crucial roles in regulating norepinephrine signaling, autonomic function, and stress responses. The receptor is unique among α2-AR subtypes for its distinctive subcellular distribution and functional properties[@szot2006].

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">ADRA2C Gene</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>ADRA2C</td></tr>
<tr><td><strong>Full Name</strong></td><td>Adrenoceptor Alpha 2C</td></tr>
<tr><td><strong>Chromosomal Location</strong></td><td>4p16.3</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[152](https://www.ncbi.nlm.nih.gov/gene/152)</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000141449</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[P21917](https://www.uniprot.org/uniprot/P21917)</td></tr>
<tr><td><strong>Protein Size</strong></td><td>462 amino acids</td></tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
</div>

Protein Structure

Transmembrane Domain Architecture

ADRA2C encodes a 462-amino acid GPCR with canonical seven transmembrane domain structure:

• 7 TM Helices (TM1-TM7): Canonical GPCR structure forming the ligand-binding pocket
• Disulfide Bond: Conserved cysteine in extracellular loop 2 that stabilizes receptor structure
• N-linked Glycosylation Sites: N-terminal extracellular domain for proper folding and trafficking
• Conserved Motifs: DRY motif in TM3 for G protein coupling, NPxxY in TM7 for activation

Functional Domains

| Domain | Location | Function |
|--------|----------|----------|
| N-terminus | Extracellular | Glycosylation, ligand access |
| Extracellular loops | ECL1-3 | Minor ligand binding contribution |
| Transmembrane core | TM1-7 | Major ligand binding site |
| Cytoplasmic loops | ICL1-3 | G protein coupling interface |
| C-terminal tail | Cytoplasmic | G protein coupling, phosphorylation sites, arrestin binding |

Molecular Function

G Protein Coupling

Alpha-2C adrenergic receptor signals primarily through Gi/o protein pathways[@wheeld2010]:

Receptor Properties

| Property | Details |
|----------|---------|
| Agonists | Norepinephrine, epinephrine, clonidine, dexmedetomidine, guanfacine |
| Antagonists | Yohimbine, rauwolscine, idazoxan, atipamezole |
| Desensitization | GRK-mediated phosphorylation, beta-arrestin recruitment |
| Internalization | Arrestin-dependent and independent pathways |
| Inverse Agonists | Several compounds that reduce constitutive activity |

Signaling Pathway

Physiological Roles

• Sympathetic Inhibition: Reduces sympathetic outflow by inhibiting norepinephrine release
• Neuronal Inhibition: Hyperpolarizes postsynaptic neurons through GIRK activation
• Presynaptic Autoreceptor: Regulates norepinephrine release from sympathetic nerve terminals
• Thermoregulation: Mediates cutaneous vasoconstriction in response to cold[@pickering2000]
• Analgesia: Spinal α2C-AR contributes to pain modulation
• Sedation: Central sedative effects of α2-AR agonists
• Cognitive Function: Modulates attention, memory, and executive function

Expression Pattern

Brain Distribution

α2C-AR exhibits distinct regional distribution:

• Cerebral Cortex: Layer-specific expression, particularly in prefrontal cortex
• Hippocampus: CA1-CA3 regions, dentate gyrus
• Basal Ganglia: Striatum (caudate and putamen), substantia nigra pars compacta
• Spinal Cord: Dorsal horn (pain transmission pathways)
• Locus Coeruleus: Noradrenergic cell bodies (presynaptic autoreceptors)
• Hypothalamus: Neuroendocrine regulation, particularly paraventricular nucleus

Peripheral Expression

• Platelets: Regulates platelet aggregation
• Adipose Tissue: Modulates lipolysis and thermogenesis
• Vasculature: Controls vascular tone, especially in cutaneous circulation
• Pancreas: Modulates insulin secretion from beta cells
• Kidney: Influences renin secretion and renal function

Disease Associations

Alzheimer's Disease

In Alzheimer's disease[@szot2006]:

• Altered α2C-AR expression in AD brain, with reduced cortical receptor density
• Contributes to noradrenergic dysfunction characteristic of AD
• Loss of cortical α2C-AR in early AD may serve as a biomarker
• Interaction with amyloid pathology through modulation of synaptic function
• Potential therapeutic target for cognitive enhancement

Parkinson's Disease

In Parkinson's disease[@chen2015]:

• Dysregulated α2-AR signaling in PD patients
• Altered autonomic function contributes to non-motor symptoms
• May affect levodopa response and motor complications
• α2-AR antagonists may have potential in treating PD psychosis
• Blunted hypothermic response to α2-AR agonists observed

Depression

The noradrenergic system is implicated in depression[@michelm2014]:

• α2-AR antagonists (e.g., yohimbine) have antidepressant effects in some patients
• Dysregulated receptor function in major depressive disorder
• Supports the noradrenergic hypothesis of depression
• α2C-AR subtype may be particularly relevant to emotional processing

Other Neurological Conditions

• Anxiety Disorders: α2C-AR role in fear and stress responses
• Pain: Spinal α2C-AR contributes to analgesic effects of α2-AR agonists
• ADHD: α2-AR agonists (guanfacine) used for attention enhancement
• Post-traumatic stress disorder: Altered adrenergic receptor function

Therapeutic Implications

Drug Targets

| Drug | Type | Application |
|------|------|-------------|
| Clonidine | Agonist | Hypertension, ADHD, opioid withdrawal |
| Dexmedetomidine | Agonist | ICU sedation, perioperative analgesia |
| Guanfacine | Agonist | ADHD, hypertension |
| Yohimbine | Antagonist | Depression, orthostatic hypotension |
| Brimonidine | Agonist | Glaucoma, ocular hypertension |

CNS Applications

• α2C-AR modulation for cognitive enhancement in AD/PD
• Selective antagonists for treatment-resistant depression
• Pain management strategies combining spinal and supraspinal mechanisms
• Combination with dopaminergic therapies in PD

Research Directions

Current research focuses on[@phelps2015]:

• Developing subtype-selective ligands with improved CNS penetration
• Understanding α2C-AR specific role in neurodegeneration
• Gene therapy approaches for direct receptor modulation
• Biomarker development using receptor imaging

See Also

• [Adrenergic Receptors](/entities/adrenergic-receptors)
• [G Protein-Coupled Receptors](/mechanisms/gpcr-signaling)
• [Noradrenergic System](/mechanisms/noradrenergic-system)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

References